COVID-19
Conditions
Keywords
NAC
Brief summary
Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.
Interventions
DRUGN-Acetyl cysteine
150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
DRUGPlacebo
Matching placebo administered in the same schedule and volume as NAC
Sponsors
Dr. Tariq Alhawassi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult above 18 years of age * Admitted to the hospital With confirmed COVID-19 by RT-PCR test * On oxygen supplement
Exclusion criteria
* Active use of NAC * Known NAC allergy * In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment * All patients enrolled in any other investigational drug studies in COVID-19.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Recovery | 28 days | Day of recovery is defined as the first day on which of the following three categories from The Ordinal Scale on Covid-19 Clinical Improvement 1. Not-Hospitalized, No limitation on activity. 2. Not Hospitalized, with limitation on activity. 3. Hospitalized, Not requiring supplemental Oxygen |
Contacts
Primary ContactBaian Alabdulbaqi, MD
Outcome results
None listed